Search

Sarepta Therapeutics to Host Analyst Q&A Regarding LGMD Programs
Patient Affairs
Community Letter: Update on Shipments of Gene Therapy for Ambulatory Individuals with Duchenne
Homepage
Products
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS